Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Net Income (2016 - 2024)

Mimedx's Net Income history spans 15 years, with the latest figure at $15.2 million for Q4 2025.

  • For Q4 2025, Net Income changed N/A year-over-year to $15.2 million; the TTM value through Dec 2025 reached $15.2 million, up 3507.84%, while the annual FY2025 figure was $48.6 million, 11438.72% up from the prior year.
  • Net Income for Q4 2025 was $15.2 million at Mimedx, up from $217000.0 in the prior quarter.
  • Across five years, Net Income topped out at $51.3 million in Q4 2023 and bottomed at -$10.9 million in Q2 2022.
  • The 5-year median for Net Income is -$1.0 million (2021), against an average of $1.5 million.
  • The largest YoY upside for Net Income was 4864.65% in 2022 against a maximum downside of 510.91% in 2022.
  • A 5-year view of Net Income shows it stood at $198000.0 in 2021, then surged by 4864.65% to $9.8 million in 2022, then soared by 421.75% to $51.3 million in 2023, then tumbled by 99.58% to $217000.0 in 2024, then surged by 6899.54% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Net Income are $15.2 million (Q4 2025), $217000.0 (Q3 2024), and $4000.0 (Q2 2024).